GlaxoSmithKline Consumer Healthcare

980 Great West Road, Brentford, Middlesex, TW8 9GS
Telephone: +44 (0)20 8047 5000
Medical Information Direct Line: +44 (0)20 8047 2500
Medical Information e-mail: customer.relations@gsk.com
Customer Care direct line: +44 (0)20 8047 2700
Medical Information Fax: +44 (0)20 8047 6860


Summary of Product Characteristics last updated on the eMC: 17/10/2011
SPC Beechams Max Strength Sore Throat Relief Blackberry Lozenges


Go to top of the page
1. NAME OF THE MEDICINAL PRODUCT

Beechams Max Strength Sore Throat Relief Blackberry Lozenges.


Go to top of the page
2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Hexylresorcinol 2.5mg and Benzalkonium Chloride Solution 1.2mg


Go to top of the page
3. PHARMACEUTICAL FORM

Lozenge


Go to top of the page
4. CLINICAL PARTICULARS

Go to top of the page
4.1 Therapeutic indications

Symptomatic relief of sore throat, the associated pain and pharyngitis.


Go to top of the page
4.2 Posology and method of administration

Adults (including the elderly) and children over the age of 12: One lozenge dissolved slowly in the mouth every three hours or as required. Do not take more than 8 lozenges in 24 hours.

Children aged 7 to 12 years: One lozenge dissolved slowly in the mouth every three hours or as required. Do not take more than 4 lozenges in 24 hours. Not to be given to children under 7 years.


Go to top of the page
4.3 Contraindications

Hypersensitivity to any of the active ingredients or excipients.

Patients with metabolic disorders relating to glucose/sucrose ingestion or fructose intolerance


Go to top of the page
4.4 Special warnings and precautions for use

Keep out of the reach and sight of children

If symptoms persist consult your doctor.

Do not exceed the stated dose

Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.

Contains 2.5 g of total glucose and sucrose per lozenge. This should be taken into account in patients with diabetes mellitus.


Go to top of the page
4.5 Interaction with other medicinal products and other forms of interaction

None


Go to top of the page
4.6 Pregnancy and lactation

There is a lack of evidence of safety of the product in human pregnancy and in animals, but both hexylresorcinol and benzalkonium chloride have been used widely in lozenges for many years without apparent ill consequence. However, as with all medicines, caution should be exercised during pregnancy and lactation.


Go to top of the page
4.7 Effects on ability to drive and use machines

None


Go to top of the page
4.8 Undesirable effects

Gastrointestinal Disorders: Local irritations or inflammations in the mouth and throat.


Go to top of the page
4.9 Overdose

The oral toxic dose of benzalkonium chloride is between 1 and 3g, symptoms of overdose are unlikely with a product containing such a low level.

An overdose of hexylresorcinol may cause minor gastrointestinal irritation.

After withdrawal of the product, treatment is symptomatic.

Theoretically symptoms are possible in children if at least 50 lozenges are consumed in a short space of time. In such extreme overdose related to menthol ingestion, symptoms may include nausea, vomiting, diarrhoea, profuse sweating and intense thirst.


Go to top of the page
5. PHARMACOLOGICAL PROPERTIES

Go to top of the page
5.1 Pharmacodynamic properties

Hexylresorcinol is a local anaesthetic effective for topical use on the mucous membranes of the mouth and throat. Mild antiseptic activity has also been demonstrated.

Benzalkonium chloride is a quaternary ammonium compound with antiseptic activity typical of this group.


Go to top of the page
5.2 Pharmacokinetic properties

Not applicable.


Go to top of the page
5.3 Preclinical safety data

There are no preclinical data of any relevance additional to that already included in other sections of the SmPC.


Go to top of the page
6. PHARMACEUTICAL PARTICULARS

Go to top of the page
6.1 List of excipients

Citric acid monohydrate, sucrose, liquid glucose, propylene glycol, blackberry flavour, levomenthol, Ponceau Red E124, Brilliant Black E151


Go to top of the page
6.2 Incompatibilities

Benzalkonium chloride is incompatible with other anionic surfactants, citrates, iodides, nitrates, permanganates, salicylates, tartrates and alkalis. Incompatibilities have also been reported with other substances including aluminium, hydrogen peroxide, kaolin and some sulphonamides.

Hexylresorcinol is also incompatible with alkalis and oxidising agents.


Go to top of the page
6.3 Shelf life

Three years


Go to top of the page
6.4 Special precautions for storage

None


Go to top of the page
6.5 Nature and contents of container

Blisters (PVC 250 microns/PVdC 60 microns/Aluminium 20 microns)

Pack sizes 10, 12, 20.

Not all pack sizes may be marketed.


Go to top of the page
6.6 Special precautions for disposal and other handling

None


Go to top of the page
7. MARKETING AUTHORISATION HOLDER

Beecham Group Plc

908 Great West Road

Brentford

Middlesex

TW8 9GS

United Kingdom

Trading as: GlaxoSmithKline Consumer Healthcare, Brentford, Middlesex, TW8 9GS, U.K.


Go to top of the page
8. MARKETING AUTHORISATION NUMBER(S)

PL 00079/0386


Go to top of the page
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

26 April 2002


Go to top of the page
10. DATE OF REVISION OF THE TEXT

26/01/2011



More information about this product

Link to this document from your website: http://www.medicines.org.uk/emc/medicine/21525/SPC/


Active Ingredients/Generics

 
   benzalkonium chloride
   hexylresorcinol